Mini-Networking Night: Startup and Entrepreneurship

Event details
Mini-Networking Night focused on Startup and Entrepreneurship will feature guests from ImmunoBiochem, Acorn Biolabs, Deep Genomics and Enrich Bioscience on April 24th, 2018. Interested in learning more about Startup culture, join us for an exciting networking night where some of the most prominent Startups in Toronto will talk about their path to success! 
Date: Tuesday, April 24th, 2018
Time: 6:00 pm – 8:00 pm
Registration: Opens on April 12, 2018
Location: 2nd floor of Prenup Pub (191 College St, Toronto), near Queen’s Park Subway Station
Event program
6:00 – 6:10 p.m. Registration
6:10 – 6:20 p.m. Welcome remarks & Guest introduction
6:20 – 7:20 p.m. Structured Networking (students are organized into groups, which 3x rotate every 20 minutes)
7:20 – 8:00 p.m. Open Networking
*Appetizers & cash bar are provided.
Note: Please follow us on social media (FacebookLinkedIn and Twitter). The call for registration for all events in the Mini-Networking Series will first go out on social media.

Very limited space available. Registered individuals who do not show up will be prevented from registering for future events.

The Mini Networking Series is free for all students, post-docs and other research trainees at the University of Toronto or the affiliated research institutions. External participants must pay a $5 fee to register.

Have more questions about registration? Visit our FAQ page.

Register Now


Tarang Khare, Ph.D., MBA,
CEO and CSO, 
Enrich Bioscience

Tarang Khare, Ph.D., MBA,

Chief Executive Officer and Chief Scientific Officer

An Epigeneticist with specialization in DNA methylation, and an MBA-2018 student of the Rotman School of Management-Toronto. He is trained at the accomplished laboratories in Belgium, Germany, and Canada and is passionate about innovating tools to study DNA methylation for research or diagnostic purposes.

Khare’s enthusiasm has led his Enrich Bioscience team to utilize a powerful tool for early detection of cancer from blood.

Anton Neschadim, Ph.D., MBA

CEO, ImmunoBiochem Inc.

Anton is a biomedical professional, scientist, innovator, entrepreneur and venture capitalist with 15 years of industry and academic experience in research and drug development. At ImmunoBiochem Corporation, Anton is leading the development of a new class of tumor microenvironment-targeted anti-cancer therapeutics. Anton was formerly the Director of Drug Development at Armour Therapeutics Inc., a biopharmaceutical company developing a new class of anti-cancer therapeutics for prostate, breast and ovarian cancers. Throughout his career, Anton worked on R&D and consulting projects with several biopharmaceutical companies developing biological therapeutics and immunotherapies in oncology. Anton has expertise in cancer research, immunology, chemistry, regenerative medicine and gene therapy, and authored more than 25 peer-reviewed publications and patents. 

Anton obtained his PhD, MSc, and Hon. BSc degrees in medical biophysics, immunology, and biological chemistry at the University of Toronto, where he also completed postdoctoral work and his MBA at the Rotman School of Management. Anton is also a graduate of the CIHR Training Program in Regenerative Medicine (TPRM), Toronto General Hospital, University Health Network. Anton was a founding board member, and former CCO and organizing committee member of the Canadian Science Policy Centre (Toronto, ON) – a national organization promoting science policy in Canada.

Steven ten Holder,

COO, Acorn Biolabs

Steven ten Holder is the founder and COO at Acorn Biolabs, a company working to commercialize mail-in cell cryopreservation to improve future healthspan and longevity. He has a background in molecular genetics from the University of Waterloo where he used synthetic biology design to create a CRISPR-powered viral immunity system in plants, and a plasmid incompatibility system to help tackle antibiotic resistance.

Patrick Pumputis, M.Sc.

Co-Founder and CSO, Acorn Biolabs

Patrick Pumputis is the Co-Founder and Chief Science Officer at Acorn Biolabs, responsible for developing the company’s technology portfolio of novel cell transport and cryopreservation media. Acorn Biolabs provides a mail-in, non-invasive cell collection kit for the cryopreservation and analysis of adult cells. Prior to founding Acorn Biolabs, Patrick completed his BSc in Biomedical Sciences and his MSc in Cell and Molecular Biology at the University of Waterloo. His thesis work developed high throughput cell analysis assays, as well as discovering key compounds responsible for cellular viability and integrity. In his spare time Patrick enjoys biking, music, and brewing beer.

Erno Wienholds, PhD
Director of Experimental Biology, Deep Genomics

Event Photos